Skip to main content
Top
Published in: Drugs & Aging 10/2015

01-10-2015 | Review Article

Tolerability of Antihypertensive Medications in Older Adults

Authors: Thiruvinvamalai S. Dharmarajan, Lekshmi Dharmarajan

Published in: Drugs & Aging | Issue 10/2015

Login to get access

Abstract

Several guidelines for hypertension have recently undergone revisions to incorporate an approach providing choices of medications based on age, race, and specific situations where hypertension may co-exist with disorders such as diabetes, coronary artery disease, heart failure and chronic kidney disease. Initial recommendations include diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers; beta blockers are favored in some guidelines and are a choice in specific settings. Within the classes of drugs, several antihypertensive agents provide options. This review discusses antihypertensive drugs by class, including adverse effects and tolerability, with preferences in older adults and specific settings. Adverse drug events from antihypertensive medications are discussed by class and where applicable for specific agents. Data from select studies pertinent to tolerability and adverse effects are presented in tables for several classes of drugs. The rationale for nonadherence to medication is reviewed, including the roles played by tolerability and adverse drug effects. Antihypertensive therapy in typical settings in older adults is discussed; they include hypertension in association with impaired cognition, depression, diabetes, sexual dysfunction, and falls. The key to successful therapy and tolerability is to promote a healthy lifestyle in conjunction with medications as the approach, thereby also lowering the adverse drug effects. The eventual choice of the specific drug(s) is based on risks, benefits, and patient preferences, and is best tailored for each older adult.
Literature
2.
go back to reference Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.PubMedCrossRef Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.PubMedCrossRef
3.
go back to reference Gillespie CD, Hurvitz KA, Centers of Disease Control and Prevention. Prevalence of hypertension and controlled hypertension—United States, 2007–2010. MMWR Surveill Summ. 2013;62(Suppl 3):144–8.PubMed Gillespie CD, Hurvitz KA, Centers of Disease Control and Prevention. Prevalence of hypertension and controlled hypertension—United States, 2007–2010. MMWR Surveill Summ. 2013;62(Suppl 3):144–8.PubMed
4.
go back to reference Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: national health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. No 133. 2013. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: national health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. No 133. 2013.
5.
go back to reference James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA. 2014;311(5):507–20.PubMedCrossRef James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA. 2014;311(5):507–20.PubMedCrossRef
6.
go back to reference Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community. A Statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertension. 2013;. doi:10.1111/jch.12237. Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community. A Statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertension. 2013;. doi:10.​1111/​jch.​12237.
7.
go back to reference Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.PubMedCrossRef Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.PubMedCrossRef
8.
go back to reference Sox HC. Assessing the trustworthiness of the guideline for management of high blood pressure in adults. JAMA. 2014;311(5):472–4.PubMedCrossRef Sox HC. Assessing the trustworthiness of the guideline for management of high blood pressure in adults. JAMA. 2014;311(5):472–4.PubMedCrossRef
9.
go back to reference Grossman E, Messerli FH. Long term safety of antihypertensive therapy. Prog Cardiovasc Dis. 2006;49(1):16–25.PubMedCrossRef Grossman E, Messerli FH. Long term safety of antihypertensive therapy. Prog Cardiovasc Dis. 2006;49(1):16–25.PubMedCrossRef
11.
go back to reference Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation and reporting. Ann Intern Med. 2004;140:795–801.PubMedCrossRef Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation and reporting. Ann Intern Med. 2004;140:795–801.PubMedCrossRef
12.
go back to reference Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356:1255–9.PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356:1255–9.PubMedCrossRef
13.
go back to reference Vongpatanasin W. Resistant hypertension. A review of diagnosis and management. JAMA. 2012;311(2):2216–24. Vongpatanasin W. Resistant hypertension. A review of diagnosis and management. JAMA. 2012;311(2):2216–24.
14.
go back to reference Dharmarajan TS. The physiology of aging. In: Dharmarajan TS, Pitchumoni CS, editors. Geriatric gastroenterology. 1st ed. New York: Springer; 2012. p. 17–31.CrossRef Dharmarajan TS. The physiology of aging. In: Dharmarajan TS, Pitchumoni CS, editors. Geriatric gastroenterology. 1st ed. New York: Springer; 2012. p. 17–31.CrossRef
15.
go back to reference Haumschild RJ. Pharmacokinetics of aging. In: Dharmarajan TS, Pitchumoni CS, editors. Geriatric gastroenterology. 1st ed. New York: Springer; 2012. p. 83–7.CrossRef Haumschild RJ. Pharmacokinetics of aging. In: Dharmarajan TS, Pitchumoni CS, editors. Geriatric gastroenterology. 1st ed. New York: Springer; 2012. p. 83–7.CrossRef
16.
go back to reference Dharmarajan TS, Davuluri S. Medications, renal function and kidney injury: a complex interplay, wherein prevention is easier than cure. JAMDA. 2014;15:692–6.PubMed Dharmarajan TS, Davuluri S. Medications, renal function and kidney injury: a complex interplay, wherein prevention is easier than cure. JAMDA. 2014;15:692–6.PubMed
17.
go back to reference Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–85.PubMedCrossRef Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–85.PubMedCrossRef
19.
go back to reference Epstein M. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106–22.PubMed Epstein M. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106–22.PubMed
20.
go back to reference Zamboni M, Zoico E, Scartezzini T, et al. Body composition changes in stable-weight elderly subjects: the effect of sex. Aging Clin Exp Res. 2003;15(4):321–7.PubMedCrossRef Zamboni M, Zoico E, Scartezzini T, et al. Body composition changes in stable-weight elderly subjects: the effect of sex. Aging Clin Exp Res. 2003;15(4):321–7.PubMedCrossRef
21.
go back to reference Buffa R, Florsi GU, Putzu PF, Marini E. Body composition variations in ageing. Coll Antropol. 2011;35(1):259–65.PubMed Buffa R, Florsi GU, Putzu PF, Marini E. Body composition variations in ageing. Coll Antropol. 2011;35(1):259–65.PubMed
22.
go back to reference Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMedCrossRef Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMedCrossRef
23.
go back to reference Gunturu SG, Dharmarajan TS. Drug-nutrient interactions. In: Dharmarajan TS, Pitchumoni CS, editors. Geriatric gastroenterology. 1st ed. New York: Springer; 2012. p. 89–98.CrossRef Gunturu SG, Dharmarajan TS. Drug-nutrient interactions. In: Dharmarajan TS, Pitchumoni CS, editors. Geriatric gastroenterology. 1st ed. New York: Springer; 2012. p. 89–98.CrossRef
24.
go back to reference Psaty BM, Lumley T, Furberg CD, et al. Health outcome associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.PubMedCrossRef Psaty BM, Lumley T, Furberg CD, et al. Health outcome associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.PubMedCrossRef
25.
go back to reference Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15(4):527–47.PubMedCrossRef Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15(4):527–47.PubMedCrossRef
26.
go back to reference Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovas Ther. 2010;8(6):793–802.CrossRef Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovas Ther. 2010;8(6):793–802.CrossRef
28.
go back to reference Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639–43.CrossRef Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639–43.CrossRef
29.
go back to reference Wehling M. Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc. 2013;14(6):437–42.PubMedCrossRef Wehling M. Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc. 2013;14(6):437–42.PubMedCrossRef
30.
go back to reference Palmar BF. Metabolic complications associated with use of diuretics. Semin Nephrol. 2011;31(6):542–52.CrossRef Palmar BF. Metabolic complications associated with use of diuretics. Semin Nephrol. 2011;31(6):542–52.CrossRef
31.
go back to reference Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults. Ann Intern Med. 2013;158:447–55.PubMedCrossRef Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults. Ann Intern Med. 2013;158:447–55.PubMedCrossRef
32.
go back to reference Rodenburg EM, Visser LE, Hoorn EJ, et al. Thiazides and the risk of hypokalemia in the general population. J Hypertens. 2014;32(10):2092–7.PubMedCrossRef Rodenburg EM, Visser LE, Hoorn EJ, et al. Thiazides and the risk of hypokalemia in the general population. J Hypertens. 2014;32(10):2092–7.PubMedCrossRef
33.
go back to reference Kotchen TS. Antihypertensive therapy-associated hypokalemia and hyperkalemia: clinical implications. Hypertension. 2012;59:906–7.PubMedCrossRef Kotchen TS. Antihypertensive therapy-associated hypokalemia and hyperkalemia: clinical implications. Hypertension. 2012;59:906–7.PubMedCrossRef
34.
go back to reference Meisinger C, Stockl D, Ruckert IM, et al. Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F$-study. Diabetologia. 2013;56(3):484–91.PubMedCrossRef Meisinger C, Stockl D, Ruckert IM, et al. Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F$-study. Diabetologia. 2013;56(3):484–91.PubMedCrossRef
35.
go back to reference Ben Salem C, Badreddine A, Fathallah N, et al. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677–92.PubMedCrossRef Ben Salem C, Badreddine A, Fathallah N, et al. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677–92.PubMedCrossRef
36.
go back to reference Chapagain A, Ashman N. Hyperkalemia in the age of aldosterone antagonism. Q J Med. 2012;105:1049–105.CrossRef Chapagain A, Ashman N. Hyperkalemia in the age of aldosterone antagonism. Q J Med. 2012;105:1049–105.CrossRef
37.
go back to reference Muschart X, Boulouffe C, Jamart J, et al. A determination of the current causes of hyperkalemia and whether they have changed over the past 25 years. Acta Clin Belg. 2014;69(4):280–4.PubMedCrossRef Muschart X, Boulouffe C, Jamart J, et al. A determination of the current causes of hyperkalemia and whether they have changed over the past 25 years. Acta Clin Belg. 2014;69(4):280–4.PubMedCrossRef
38.
go back to reference Uijtendaal EV, Zwart-van Rijkom JE, van Solinge WW, Eqberts TC. Serum potassium influencing interacting drugs: risk-modifying strategies also needed at discontinuation. Ann Pharmacother. 2012;46(2):176–82.PubMedCrossRef Uijtendaal EV, Zwart-van Rijkom JE, van Solinge WW, Eqberts TC. Serum potassium influencing interacting drugs: risk-modifying strategies also needed at discontinuation. Ann Pharmacother. 2012;46(2):176–82.PubMedCrossRef
39.
go back to reference Berkova M, Berka Z, Topinkova E. Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(1):84–91.PubMed Berkova M, Berka Z, Topinkova E. Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(1):84–91.PubMed
40.
go back to reference Alderman MH, Piler LB, Ford CE, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in ALLHAT. Hypertension. 2012;59(5):926–33.PubMedCentralPubMedCrossRef Alderman MH, Piler LB, Ford CE, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in ALLHAT. Hypertension. 2012;59(5):926–33.PubMedCentralPubMedCrossRef
41.
go back to reference Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011;124(11):1064–72.PubMedCrossRef Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011;124(11):1064–72.PubMedCrossRef
42.
go back to reference Van Blijderveen JC, Straus SM, Rodenburg EM, et al. Risk of hyponatremia with diuretics: chlortalidone versus hydrochlorothiazide. Am J Med. 2014;127(8):763–71.PubMedCrossRef Van Blijderveen JC, Straus SM, Rodenburg EM, et al. Risk of hyponatremia with diuretics: chlortalidone versus hydrochlorothiazide. Am J Med. 2014;127(8):763–71.PubMedCrossRef
43.
go back to reference Barber J, McKeever TM, McDowell SE, et al. A systematic review and meta-analysis of thiazide-induced hyponatremia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol. 2014. doi:10.1111/bcp.12499 (Epub ahead of print). Barber J, McKeever TM, McDowell SE, et al. A systematic review and meta-analysis of thiazide-induced hyponatremia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol. 2014. doi:10.​1111/​bcp.​12499 (Epub ahead of print).
44.
go back to reference Khow KS, Lau SY, Li JY, Yong TY. Diuretic-associated electrolyte disorders in the elderly: risk factors, impact, management and prevention. Curr Drug Saf. 2014;9(1):2–15.PubMedCrossRef Khow KS, Lau SY, Li JY, Yong TY. Diuretic-associated electrolyte disorders in the elderly: risk factors, impact, management and prevention. Curr Drug Saf. 2014;9(1):2–15.PubMedCrossRef
45.
go back to reference Al Qahtani M, Alshahrani A, Alskaini A et al. Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: single center retrospective study. Saudi J Kidney Dis Transpl. 2013;24(2):281–5. Al Qahtani M, Alshahrani A, Alskaini A et al. Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: single center retrospective study. Saudi J Kidney Dis Transpl. 2013;24(2):281–5.
46.
go back to reference Chow KM, Szeto CC, Wong TY, et al. Risk factors for thiazide-induced hyponatremia. QJM. 2003;96(12):911–7.PubMedCrossRef Chow KM, Szeto CC, Wong TY, et al. Risk factors for thiazide-induced hyponatremia. QJM. 2003;96(12):911–7.PubMedCrossRef
47.
go back to reference Rodenburg EM, Hoorn EJ, Ruiter R, et al. Thiazide-induced hyponatremia: a population based study. Am J Kidney Dis. 2013;62(1):67–72.PubMedCrossRef Rodenburg EM, Hoorn EJ, Ruiter R, et al. Thiazide-induced hyponatremia: a population based study. Am J Kidney Dis. 2013;62(1):67–72.PubMedCrossRef
48.
go back to reference Rastogi D, Pelter MA, Deamer RL. Evaluations of hospitalizations associated with thiazide-associated hyponatremia. J Clin Hypertens (Greenwich). 2012;14(3):158–64.CrossRef Rastogi D, Pelter MA, Deamer RL. Evaluations of hospitalizations associated with thiazide-associated hyponatremia. J Clin Hypertens (Greenwich). 2012;14(3):158–64.CrossRef
49.
go back to reference Yamada H, Asano T, Aoki A, et al. Combination therapy of angiotensin II receptor blocker and thiazide produces severe hyponatremia in elderly hypertensive subjects. Intern Med. 2014;53:749–52.PubMedCrossRef Yamada H, Asano T, Aoki A, et al. Combination therapy of angiotensin II receptor blocker and thiazide produces severe hyponatremia in elderly hypertensive subjects. Intern Med. 2014;53:749–52.PubMedCrossRef
50.
51.
go back to reference Sharbi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatremia in elderly hypertensive women. J Hum Hypertens. 2002;16:631–5.CrossRef Sharbi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatremia in elderly hypertensive women. J Hum Hypertens. 2002;16:631–5.CrossRef
52.
go back to reference Yong TY, Huang JE, Lau SY, Li JY. Severe hyponatremia and other electrolyte disturbances associated with indapamide. Curr Drug Saf. 2011;6(3):134–7.PubMedCrossRef Yong TY, Huang JE, Lau SY, Li JY. Severe hyponatremia and other electrolyte disturbances associated with indapamide. Curr Drug Saf. 2011;6(3):134–7.PubMedCrossRef
53.
go back to reference Glover M, Clayton J. thiazide-induced hyponatremia: epidemiology and clues to pathogenesis. Cardiovasc Ther. 2012;30(5):e219–26.PubMedCrossRef Glover M, Clayton J. thiazide-induced hyponatremia: epidemiology and clues to pathogenesis. Cardiovasc Ther. 2012;30(5):e219–26.PubMedCrossRef
54.
go back to reference Arampatzis S, Gaetcke LM, Funk GC, et al. Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas. 2013;75(1):81–6.PubMedCrossRef Arampatzis S, Gaetcke LM, Funk GC, et al. Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas. 2013;75(1):81–6.PubMedCrossRef
55.
go back to reference Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299–308.PubMedCrossRef Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299–308.PubMedCrossRef
56.
go back to reference Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalideone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82.PubMedCrossRef Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalideone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82.PubMedCrossRef
57.
go back to reference Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17(5–6):397–414.PubMedCrossRef Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17(5–6):397–414.PubMedCrossRef
58.
go back to reference Gibson TJ. Hypertension, its treatment, hyperuricaemia and gout. Curr Clin Rheumatol. 2013;25(2):217–22.CrossRef Gibson TJ. Hypertension, its treatment, hyperuricaemia and gout. Curr Clin Rheumatol. 2013;25(2):217–22.CrossRef
59.
go back to reference Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1887;50(8):953–9.CrossRef Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1887;50(8):953–9.CrossRef
61.
go back to reference Diaconu CC, Balaceanu A, Bartos D. Diuretics, first-line antihypertensive agents: are they always safe in the elderly? Rom J Intern Med. 2014;52(2):87–90.PubMed Diaconu CC, Balaceanu A, Bartos D. Diuretics, first-line antihypertensive agents: are they always safe in the elderly? Rom J Intern Med. 2014;52(2):87–90.PubMed
62.
go back to reference Udea S, Morimoto T, Ando S, et al. A randomized controlled trial for the evaluation of risk for type 3 diabetes in hypertensive patients receiving thiazide diuretics: diuretics in the management of essential hypertension (DIME) study. BMJ Open. 2014;4:e004576.CrossRef Udea S, Morimoto T, Ando S, et al. A randomized controlled trial for the evaluation of risk for type 3 diabetes in hypertensive patients receiving thiazide diuretics: diuretics in the management of essential hypertension (DIME) study. BMJ Open. 2014;4:e004576.CrossRef
63.
go back to reference Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium - a meta-analysis. J Am Soc Hypertens. 2013;7(6):454–66.PubMedCrossRef Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium - a meta-analysis. J Am Soc Hypertens. 2013;7(6):454–66.PubMedCrossRef
64.
go back to reference Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol. 2014;66(1):185–96.PubMedCrossRef Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol. 2014;66(1):185–96.PubMedCrossRef
65.
go back to reference Arampatzis S, Funk GS, Leichtle AB, et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department : a cross-sectional analysis. BMC Med. 2013;11:83.PubMedCentralPubMedCrossRef Arampatzis S, Funk GS, Leichtle AB, et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department : a cross-sectional analysis. BMC Med. 2013;11:83.PubMedCentralPubMedCrossRef
66.
go back to reference Regulski M, Regulska K, Stanisz BJ, et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des. 2015;21(13):1764–75.PubMedCrossRef Regulski M, Regulska K, Stanisz BJ, et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des. 2015;21(13):1764–75.PubMedCrossRef
67.
69.
go back to reference Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010;24(9):600–8.PubMedCrossRef Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010;24(9):600–8.PubMedCrossRef
70.
go back to reference Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014;34(3):273–84.PubMedCrossRef Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014;34(3):273–84.PubMedCrossRef
71.
go back to reference Powers BJ, Coeytaux RR, Dolor RJ, et al. updated report on comparative effectiveness of ACE inhibitors, ARBS and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2011;27(6):716–29.PubMedCentralPubMedCrossRef Powers BJ, Coeytaux RR, Dolor RJ, et al. updated report on comparative effectiveness of ACE inhibitors, ARBS and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2011;27(6):716–29.PubMedCentralPubMedCrossRef
72.
go back to reference Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8:CD009096. doi:10.1002/14651858.CD009096.pub2. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8:CD009096. doi:10.​1002/​14651858.​CD009096.​pub2.
73.
go back to reference Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12(4):263–77.PubMedCrossRef Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12(4):263–77.PubMedCrossRef
74.
go back to reference Grilo A, Saez-Rosas MP, Santos-Morano J, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics. 2011;21(1):10–7.PubMedCrossRef Grilo A, Saez-Rosas MP, Santos-Morano J, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics. 2011;21(1):10–7.PubMedCrossRef
75.
go back to reference Mahmoudpour SH, Leusink M, van der Putten L, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics. 2013;14(3):249–60.PubMedCrossRef Mahmoudpour SH, Leusink M, van der Putten L, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics. 2013;14(3):249–60.PubMedCrossRef
76.
go back to reference Ng LP, Goh PS. Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare center in Singapore. Singapore Med J. 2014;55(3):146–9.PubMedCentralPubMedCrossRef Ng LP, Goh PS. Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare center in Singapore. Singapore Med J. 2014;55(3):146–9.PubMedCentralPubMedCrossRef
77.
go back to reference Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13(4):337–44.PubMedCrossRef Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13(4):337–44.PubMedCrossRef
78.
go back to reference Bezalel S, Mahlab-Guri K, Asher I, et al. Angiotensin converting enzyme inhibitor induced angioedema. Am J Med. 2015;128:120–5.PubMedCrossRef Bezalel S, Mahlab-Guri K, Asher I, et al. Angiotensin converting enzyme inhibitor induced angioedema. Am J Med. 2015;128:120–5.PubMedCrossRef
79.
go back to reference Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172(20):1582–9.PubMedCrossRef Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172(20):1582–9.PubMedCrossRef
80.
go back to reference Beavers CJ, Dunn SP, Macaulay TE. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother. 2011;45(4):520–4.PubMedCrossRef Beavers CJ, Dunn SP, Macaulay TE. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother. 2011;45(4):520–4.PubMedCrossRef
81.
go back to reference Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002;22(9):1173–5.PubMedCrossRef Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002;22(9):1173–5.PubMedCrossRef
83.
go back to reference Sidorenkov G, Navis G. Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opin Drug Saf. 2014;13(10):1383–95.PubMedCrossRef Sidorenkov G, Navis G. Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opin Drug Saf. 2014;13(10):1383–95.PubMedCrossRef
84.
go back to reference Zeravica R, Stosic Z, Ilincic B, et al. The effect of angiotensin converting enzyme inhibition on effective renal plasma flow in patients with diffuse renal parenchymal diseases and hypertension. Med Pregl. 2014;67(3–4):78–82.PubMedCrossRef Zeravica R, Stosic Z, Ilincic B, et al. The effect of angiotensin converting enzyme inhibition on effective renal plasma flow in patients with diffuse renal parenchymal diseases and hypertension. Med Pregl. 2014;67(3–4):78–82.PubMedCrossRef
86.
go back to reference Mateti UV, Nekkanti H, Viakkathala R, et al. Pattern of angiotensin-converting enzyme inhibitors induced adverse reactions in a South Indian Teaching hospital. N Am J med Sci. 2012;4(4):185–9.PubMedCentralPubMedCrossRef Mateti UV, Nekkanti H, Viakkathala R, et al. Pattern of angiotensin-converting enzyme inhibitors induced adverse reactions in a South Indian Teaching hospital. N Am J med Sci. 2012;4(4):185–9.PubMedCentralPubMedCrossRef
87.
go back to reference Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156–66.PubMedCrossRef Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156–66.PubMedCrossRef
88.
89.
go back to reference Ben Sallem C, Badreddine A, Fathallah N, et al. Drug-induced hyperkalemia. Drugs Saf. 2014;37(9):677–92.CrossRef Ben Sallem C, Badreddine A, Fathallah N, et al. Drug-induced hyperkalemia. Drugs Saf. 2014;37(9):677–92.CrossRef
90.
go back to reference Surabenjawong U, Thunpiphat N, Chatsiricharoenkul S, Monsomboon A. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. J Med Assoc Thai. 2013;96(8):905–10.PubMed Surabenjawong U, Thunpiphat N, Chatsiricharoenkul S, Monsomboon A. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. J Med Assoc Thai. 2013;96(8):905–10.PubMed
91.
go back to reference Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30(5):418–24 (A28). Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30(5):418–24 (A28).
92.
go back to reference Neil-Dwyer G, Marus A. ACE inhibitors in hypertension: assessment of taste and smell function in clinical trials. J Hum Hypertens. 1989;3(Suppl 1):169–76.PubMed Neil-Dwyer G, Marus A. ACE inhibitors in hypertension: assessment of taste and smell function in clinical trials. J Hum Hypertens. 1989;3(Suppl 1):169–76.PubMed
94.
go back to reference Unnikrishnan D, Murakonda P, Dharmarajan TS. If it is not cough, it must be dysguesia. Differing adverse effects of angiotensin-converting enzyme inhibitors in the same individual. J Am Med Dir Assoc. 2004;5:107–110. Unnikrishnan D, Murakonda P, Dharmarajan TS. If it is not cough, it must be dysguesia. Differing adverse effects of angiotensin-converting enzyme inhibitors in the same individual. J Am Med Dir Assoc. 2004;5:107–110.
95.
go back to reference Powers B, Greene L, Balfe LM. Updates on the treatment of essential hypertension: a summary of AHRQ’s comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm. 2011;17(8 Suppl):S1–14.PubMed Powers B, Greene L, Balfe LM. Updates on the treatment of essential hypertension: a summary of AHRQ’s comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm. 2011;17(8 Suppl):S1–14.PubMed
96.
go back to reference Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am J Med. 2011;123(11):1016–30.CrossRef Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am J Med. 2011;123(11):1016–30.CrossRef
97.
go back to reference Kaiser EA, Lotze U, Schafer HH. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? Clin Interv Aging. 2014;9:259–75. Kaiser EA, Lotze U, Schafer HH. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? Clin Interv Aging. 2014;9:259–75.
98.
99.
go back to reference Poirier L, Tobe SW. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30:S9–15.PubMedCrossRef Poirier L, Tobe SW. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30:S9–15.PubMedCrossRef
100.
go back to reference Larochelle P, Tobe SW, Lacourciere Y. β-blockers in hypertension: studies and meta-analysis over the years. Can J Cardiol. 2014;30:S16–22.PubMedCrossRef Larochelle P, Tobe SW, Lacourciere Y. β-blockers in hypertension: studies and meta-analysis over the years. Can J Cardiol. 2014;30:S16–22.PubMedCrossRef
101.
go back to reference Howlett JG. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease. Can J Cardiol. 2014;30:S29–37.PubMedCrossRef Howlett JG. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease. Can J Cardiol. 2014;30:S29–37.PubMedCrossRef
103.
go back to reference Mancia G, Parodi A, Merlino I, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens. 2011;29:1012–8.PubMedCrossRef Mancia G, Parodi A, Merlino I, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens. 2011;29:1012–8.PubMedCrossRef
104.
go back to reference Richards TR, Tobe SW. Combining other antihypertensive drugs with β-blockers in hypertension: A focus on safety and tolerability. Can J Cardiol. 2014;30:S42–6.PubMedCrossRef Richards TR, Tobe SW. Combining other antihypertensive drugs with β-blockers in hypertension: A focus on safety and tolerability. Can J Cardiol. 2014;30:S42–6.PubMedCrossRef
105.
go back to reference Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens. 2011;13(9):687–9.CrossRef Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens. 2011;13(9):687–9.CrossRef
106.
go back to reference Thulin T. Calcium antagonists—assessment of side effects. Scand J Prim Health Care Suppl. 1990;1:81–4.PubMed Thulin T. Calcium antagonists—assessment of side effects. Scand J Prim Health Care Suppl. 1990;1:81–4.PubMed
107.
go back to reference Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issue and practical significance. J Clin Hypertens (Greenwich). 2003;5(5):330–5.CrossRef Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issue and practical significance. J Clin Hypertens (Greenwich). 2003;5(5):330–5.CrossRef
108.
go back to reference Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996;15(2):91–106.PubMedCrossRef Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996;15(2):91–106.PubMedCrossRef
109.
go back to reference Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544–53.PubMedCrossRef Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544–53.PubMedCrossRef
110.
go back to reference Cikrikcioglu MA, Karatoprak C, Cakirca M, et al. Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease. Eur Rev Med Pharmacol Sci. 2013;17(16):2530–7.PubMed Cikrikcioglu MA, Karatoprak C, Cakirca M, et al. Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease. Eur Rev Med Pharmacol Sci. 2013;17(16):2530–7.PubMed
111.
go back to reference Denolle T, Sassano P, Allain H, et al. Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients. Fundam Clin Pharmacol. 2002;26(6):527–35.CrossRef Denolle T, Sassano P, Allain H, et al. Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients. Fundam Clin Pharmacol. 2002;26(6):527–35.CrossRef
112.
go back to reference Delaney J, Spevack D, Doddamani S, Ostfeld R. Clonidine-induced delirium. Int J Cardiol. 2006;113(2):276–8.PubMedCrossRef Delaney J, Spevack D, Doddamani S, Ostfeld R. Clonidine-induced delirium. Int J Cardiol. 2006;113(2):276–8.PubMedCrossRef
113.
go back to reference Campanella C, Salvini S, Casaldi S, et al. Clonidine hallucinations: description of a clinical case. Clin Ter. 2000;151(1):45–7.PubMed Campanella C, Salvini S, Casaldi S, et al. Clonidine hallucinations: description of a clinical case. Clin Ter. 2000;151(1):45–7.PubMed
114.
go back to reference Abo-Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazipine and clonidine. Pharmacotherapy. 2000;20(4):476–8.PubMedCrossRef Abo-Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazipine and clonidine. Pharmacotherapy. 2000;20(4):476–8.PubMedCrossRef
115.
go back to reference Rossitto G, Kamath G, Messerli FH. Should alpha blockers ever be used as antihypertensive drugs? Cleve Clin J Med. 2010;77(12):884–8.PubMedCrossRef Rossitto G, Kamath G, Messerli FH. Should alpha blockers ever be used as antihypertensive drugs? Cleve Clin J Med. 2010;77(12):884–8.PubMedCrossRef
116.
go back to reference Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283:1967–75. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283:1967–75.
118.
go back to reference Yokoyama T, Hara R, Fukumoto K, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011;18(3):225–30.PubMedCrossRef Yokoyama T, Hara R, Fukumoto K, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011;18(3):225–30.PubMedCrossRef
120.
go back to reference Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357–74.PubMedCrossRef Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357–74.PubMedCrossRef
121.
go back to reference Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19(3):338–47.PubMedCrossRef Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19(3):338–47.PubMedCrossRef
122.
go back to reference Mahfouz A, Mahmoud AN, Ashfaq PA, Siyabi KH. A case report of hydralazine-induced skin reaction: Probable epidermal necrolysis (TEN). Am J Case Rep. 2012;15:135–8. Mahfouz A, Mahmoud AN, Ashfaq PA, Siyabi KH. A case report of hydralazine-induced skin reaction: Probable epidermal necrolysis (TEN). Am J Case Rep. 2012;15:135–8.
123.
go back to reference Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus with cardiac tamponade: a case report and literature review. Can J Cardiol. 2014;30(2):247.e11–247.e12. Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus with cardiac tamponade: a case report and literature review. Can J Cardiol. 2014;30(2):247.e11–247.e12.
124.
go back to reference Van der Ward V, Logan P, Conroy S, et al. Antihypertensive treatment in people with dementia. J Am Med Dir Assoc. 2014;15(9):620–9.CrossRef Van der Ward V, Logan P, Conroy S, et al. Antihypertensive treatment in people with dementia. J Am Med Dir Assoc. 2014;15(9):620–9.CrossRef
125.
go back to reference Gao Y, O’Caoimh R, Healy L, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013;3(7). doi:10.1136/bmjopen-2013-002881 (pii:e002881). Gao Y, O’Caoimh R, Healy L, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013;3(7). doi:10.​1136/​bmjopen-2013-002881 (pii:e002881).
126.
go back to reference Welsh TJ, Gladman JR, Gordon AL. The treatment of hypertension in people with dementia: a systematic review of observational studies. BMC Geriatr. 2014;14:19.PubMedCentralPubMedCrossRef Welsh TJ, Gladman JR, Gordon AL. The treatment of hypertension in people with dementia: a systematic review of observational studies. BMC Geriatr. 2014;14:19.PubMedCentralPubMedCrossRef
127.
go back to reference Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113–30.PubMedCrossRef Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113–30.PubMedCrossRef
128.
go back to reference Simonson W, Han LF, Davidson HE. Hypertension treatment and outcomes in US nursing homes: results from the US National Nursing Home Survey. J Am Med Dir Assoc. 2011;12(1):44–9.PubMedCrossRef Simonson W, Han LF, Davidson HE. Hypertension treatment and outcomes in US nursing homes: results from the US National Nursing Home Survey. J Am Med Dir Assoc. 2011;12(1):44–9.PubMedCrossRef
129.
go back to reference Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: a meta-analysis of prospective studies. J Hypertens. 2012;30(5):842–51.PubMedCrossRef Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: a meta-analysis of prospective studies. J Hypertens. 2012;30(5):842–51.PubMedCrossRef
130.
go back to reference Gentil L, Vasiliadis HM, Preville M, et al. Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults. J Am Geriatr Soc. 2012;60(12):2297–301.PubMedCrossRef Gentil L, Vasiliadis HM, Preville M, et al. Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults. J Am Geriatr Soc. 2012;60(12):2297–301.PubMedCrossRef
131.
go back to reference Bautista LE, Vera-Cala LM, Colombo C, Smith P. Symptoms of depression and anxiety and adherence to antihypertensive medication. Am J Hypertens. 2012;25(4):505–11 (S36).PubMedCentralPubMedCrossRef Bautista LE, Vera-Cala LM, Colombo C, Smith P. Symptoms of depression and anxiety and adherence to antihypertensive medication. Am J Hypertens. 2012;25(4):505–11 (S36).PubMedCentralPubMedCrossRef
132.
go back to reference Sjosten N, Nabi H, Westerlund H, et al. Effect of depression onset on adherence to medication among hypertensive patients: a longitudinal modeling study. J Hypertens. 2013;31(7):1477–84.PubMedCrossRef Sjosten N, Nabi H, Westerlund H, et al. Effect of depression onset on adherence to medication among hypertensive patients: a longitudinal modeling study. J Hypertens. 2013;31(7):1477–84.PubMedCrossRef
133.
go back to reference Michal M, Wiltink J, Lackner K, et al. Association of hypertension with depression in the community: results from the Gutenberg health Study. 2013;31(5):893–9. Michal M, Wiltink J, Lackner K, et al. Association of hypertension with depression in the community: results from the Gutenberg health Study. 2013;31(5):893–9.
134.
go back to reference Cene CW, Dennison CR, Powell HW, et al. Antihypertensive medication nonadherence in black men: direct and mediating effects of depressive symptoms, psychosocial stressors and substance use. J Clin Hypertens (Greenwich). 2013;15(3):201–9.PubMedCentralCrossRef Cene CW, Dennison CR, Powell HW, et al. Antihypertensive medication nonadherence in black men: direct and mediating effects of depressive symptoms, psychosocial stressors and substance use. J Clin Hypertens (Greenwich). 2013;15(3):201–9.PubMedCentralCrossRef
135.
136.
go back to reference Al Khaja KA, Sequeira RP, al Damanhori AH, Mathur VS. Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study. Pharmacoepidemiol Drug Saf. 2003;12(3):203–12.PubMedCrossRef Al Khaja KA, Sequeira RP, al Damanhori AH, Mathur VS. Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study. Pharmacoepidemiol Drug Saf. 2003;12(3):203–12.PubMedCrossRef
137.
go back to reference Manolis A, Doumas M. Sexyal dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26(11):2074–84.PubMedCrossRef Manolis A, Doumas M. Sexyal dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26(11):2074–84.PubMedCrossRef
138.
go back to reference Karavitakis M, Komninos C, Theodorakis PN, et al. Evaluation of sexual function in hypertensive men receiving treatment: a review of current guideline recommendation. J Sex Med. 2011;8(9):2405–14.PubMedCrossRef Karavitakis M, Komninos C, Theodorakis PN, et al. Evaluation of sexual function in hypertensive men receiving treatment: a review of current guideline recommendation. J Sex Med. 2011;8(9):2405–14.PubMedCrossRef
139.
go back to reference Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65(6):773–86.PubMedCrossRef Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65(6):773–86.PubMedCrossRef
140.
go back to reference Nicolai MPJ, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J. 2014;22:11–9.PubMedCentralPubMedCrossRef Nicolai MPJ, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J. 2014;22:11–9.PubMedCentralPubMedCrossRef
141.
go back to reference Cordero A, Bertomeu-Martinez V, Mazon P, et al. Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension. Post Grad Med. 2010;122(6):51–6.CrossRef Cordero A, Bertomeu-Martinez V, Mazon P, et al. Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension. Post Grad Med. 2010;122(6):51–6.CrossRef
142.
go back to reference La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry. 2015;48(1):1–6.PubMed La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry. 2015;48(1):1–6.PubMed
143.
go back to reference Spatz ES, Canavan ME, Desai MM, et al. Sexual activity and function among middle-aged and older men and women with hypertension. J Hypertens. 2013;31(6):1096–105.PubMedCrossRef Spatz ES, Canavan ME, Desai MM, et al. Sexual activity and function among middle-aged and older men and women with hypertension. J Hypertens. 2013;31(6):1096–105.PubMedCrossRef
144.
go back to reference Cordero A, Bertomeu-Martinez V, Mazon P, et al. Erective dysfunction in high-risk hypertensive patients treated with beta blockade agents. Cardiovasc Ther. 2010;28(1):15–22.PubMedCrossRef Cordero A, Bertomeu-Martinez V, Mazon P, et al. Erective dysfunction in high-risk hypertensive patients treated with beta blockade agents. Cardiovasc Ther. 2010;28(1):15–22.PubMedCrossRef
145.
go back to reference Yang L, Yu J, Ma R, et al. The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial. Cardiology. 2013;125(4):235–41.PubMedCrossRef Yang L, Yu J, Ma R, et al. The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial. Cardiology. 2013;125(4):235–41.PubMedCrossRef
146.
go back to reference Ekman E, Hagg S, Sundstrom A, Werkstrom V. Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type I receptor blockers. Drug Health Patient Saf. 2010;2:21–5.CrossRef Ekman E, Hagg S, Sundstrom A, Werkstrom V. Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type I receptor blockers. Drug Health Patient Saf. 2010;2:21–5.CrossRef
147.
go back to reference Fogari R, Zoppi A. Effect of antihypertensive agents of quality of life in the elderly. Drugs Aging. 2004;21(6):377–93.PubMedCrossRef Fogari R, Zoppi A. Effect of antihypertensive agents of quality of life in the elderly. Drugs Aging. 2004;21(6):377–93.PubMedCrossRef
148.
go back to reference Vertkin AL, Vilkovyskii FA, Skootnikov AS, et al. Medical and social implications of sexual dysfunction and safety of antihypertensive therapy in hypertensive patients. Kardiologiia. 2011;51(10):46–52.PubMed Vertkin AL, Vilkovyskii FA, Skootnikov AS, et al. Medical and social implications of sexual dysfunction and safety of antihypertensive therapy in hypertensive patients. Kardiologiia. 2011;51(10):46–52.PubMed
150.
go back to reference Fraga-Silva RA, Montecucco F, Mach F, et al. Pathophysiological role of the renin-angiotensin system on erective dysfunction. Eur J Clin Invest. 2013;43(9):978–86.PubMedCrossRef Fraga-Silva RA, Montecucco F, Mach F, et al. Pathophysiological role of the renin-angiotensin system on erective dysfunction. Eur J Clin Invest. 2013;43(9):978–86.PubMedCrossRef
151.
go back to reference Fonseca V, Sharma PP, Shah M, Deedwania P. Risk of new onset diabetes mellitus associated with beta-blocker treatment for hypertension. Curr Med Res Opin. 2011;27(4):799–807.PubMedCrossRef Fonseca V, Sharma PP, Shah M, Deedwania P. Risk of new onset diabetes mellitus associated with beta-blocker treatment for hypertension. Curr Med Res Opin. 2011;27(4):799–807.PubMedCrossRef
152.
go back to reference Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res. 2012;24(6):217–20.PubMedCrossRef Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res. 2012;24(6):217–20.PubMedCrossRef
153.
go back to reference Patel BM, Mehta AA. Choice of antihypertensive agents in diabetic subjects. Diabetes Vasc Dis Res. 2013;10(5):385–96.CrossRef Patel BM, Mehta AA. Choice of antihypertensive agents in diabetic subjects. Diabetes Vasc Dis Res. 2013;10(5):385–96.CrossRef
156.
go back to reference Stears AJ, Woods SH, Watts MM, et al. A double blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934–42.PubMedCrossRef Stears AJ, Woods SH, Watts MM, et al. A double blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934–42.PubMedCrossRef
157.
go back to reference Elliott WJ. Effects of potassium-sparing versus thiazide diuretics on glucose tolerance: new data on an old topic. Hypertension. 2012;59:911–2.PubMedCrossRef Elliott WJ. Effects of potassium-sparing versus thiazide diuretics on glucose tolerance: new data on an old topic. Hypertension. 2012;59:911–2.PubMedCrossRef
158.
go back to reference Zang G. Antihypertensive drugs and the risk of fall injuries: a systematic review and meta-analysis. J Int Med Res. 2013;41(5):1408–17.PubMedCrossRef Zang G. Antihypertensive drugs and the risk of fall injuries: a systematic review and meta-analysis. J Int Med Res. 2013;41(5):1408–17.PubMedCrossRef
159.
go back to reference Lipsitz LA, Habtemariam D, Gagnon M, et al. Reexamining the effect of antihypertensive medications on falls in old age. Hypertension. 2015;66(1):183–9.PubMedCrossRef Lipsitz LA, Habtemariam D, Gagnon M, et al. Reexamining the effect of antihypertensive medications on falls in old age. Hypertension. 2015;66(1):183–9.PubMedCrossRef
160.
go back to reference Butt DA, Mamdani M, Austin PC, et al. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporosis Int. 2013;24(10):2649–57.CrossRef Butt DA, Mamdani M, Austin PC, et al. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporosis Int. 2013;24(10):2649–57.CrossRef
161.
go back to reference Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172(22):1739–44.PubMedCrossRef Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172(22):1739–44.PubMedCrossRef
162.
go back to reference Callisaya ML, Sharman JE, Close J, et al. Greater daily defined dose of antihypertensive medication increases the risk of falls in older people—a population-based study. J Am Geriatr Soc. 2014;62(8):1527–33.PubMedCrossRef Callisaya ML, Sharman JE, Close J, et al. Greater daily defined dose of antihypertensive medication increases the risk of falls in older people—a population-based study. J Am Geriatr Soc. 2014;62(8):1527–33.PubMedCrossRef
163.
go back to reference Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):585–95.CrossRef Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):585–95.CrossRef
164.
go back to reference Huang SY, Zhu SX, Zeng BW, et al. Frusemide plus doxasosin therapy for nocturia in patients with BPH/LUTS. Zhonghua Nan Ke Xue. 2010;16(9):807–10.PubMed Huang SY, Zhu SX, Zeng BW, et al. Frusemide plus doxasosin therapy for nocturia in patients with BPH/LUTS. Zhonghua Nan Ke Xue. 2010;16(9):807–10.PubMed
165.
go back to reference Kojima T, Akishita M, Iijima K, et al. Nocturia in elderly people with hypertension—no influence of low-dose thiazide added to losartan. J Am Geriatr Soc. 2008;56(11):2155–6.PubMedCrossRef Kojima T, Akishita M, Iijima K, et al. Nocturia in elderly people with hypertension—no influence of low-dose thiazide added to losartan. J Am Geriatr Soc. 2008;56(11):2155–6.PubMedCrossRef
166.
go back to reference Alcantrara C, Edmondson D, Moise N, et al. Anxiety sensitivity and medication nonadherence in patients with uncontrolled hypertension. J Psychosom Res. 2014;77(4):283–6.CrossRef Alcantrara C, Edmondson D, Moise N, et al. Anxiety sensitivity and medication nonadherence in patients with uncontrolled hypertension. J Psychosom Res. 2014;77(4):283–6.CrossRef
167.
go back to reference Cene CW, Dennison CR, Powell HW, et al. Antihypertensive medication nonadherence in black men: direct and mediating effects of depressive symptoms, psychosocial stressors and substance use. J Clin Hypertens (Greeenwich). 2013;15(3):201–9.CrossRef Cene CW, Dennison CR, Powell HW, et al. Antihypertensive medication nonadherence in black men: direct and mediating effects of depressive symptoms, psychosocial stressors and substance use. J Clin Hypertens (Greeenwich). 2013;15(3):201–9.CrossRef
168.
go back to reference Gosmanova EO, Lu JL, Streja E, et al. Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension. 2014;64(5):951–7.PubMedPubMedCentralCrossRef Gosmanova EO, Lu JL, Streja E, et al. Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension. 2014;64(5):951–7.PubMedPubMedCentralCrossRef
169.
go back to reference Liu Q, Quan H, Chen G, et al. Antihypertensive medication adherence and mortality according to ethnicity. Can J Cardiol. 2014;30(8):925–31.PubMedCrossRef Liu Q, Quan H, Chen G, et al. Antihypertensive medication adherence and mortality according to ethnicity. Can J Cardiol. 2014;30(8):925–31.PubMedCrossRef
170.
go back to reference Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7(1):46–60.PubMedCrossRef Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7(1):46–60.PubMedCrossRef
171.
go back to reference Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomized controlled trial in primary care. BMJ. 2014;27(348):g3318.CrossRef Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomized controlled trial in primary care. BMJ. 2014;27(348):g3318.CrossRef
172.
go back to reference Bramiage P, Zemmrich C, Ketelhut R, et al. Safety, tolerability and efficacy of a fixed dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Vasc Health Risk Manage. 2013;9:475–83.CrossRef Bramiage P, Zemmrich C, Ketelhut R, et al. Safety, tolerability and efficacy of a fixed dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Vasc Health Risk Manage. 2013;9:475–83.CrossRef
173.
go back to reference Ferdinand KC, Nasser SA. A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. 2013;13(5):301–13. Ferdinand KC, Nasser SA. A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. 2013;13(5):301–13.
174.
go back to reference Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker and a thiazide diuretic. Vasc Health Risk Manage. 2012;8:371–80.CrossRef Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker and a thiazide diuretic. Vasc Health Risk Manage. 2012;8:371–80.CrossRef
175.
go back to reference Yusuf S, Pais P, Sigammani A, et al. Comparison of risk factor reduction and tolerability of a full dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) Investigators. Circ Cardiovasc Qual Outcomes. 2012;5:463–71.PubMedCrossRef Yusuf S, Pais P, Sigammani A, et al. Comparison of risk factor reduction and tolerability of a full dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) Investigators. Circ Cardiovasc Qual Outcomes. 2012;5:463–71.PubMedCrossRef
177.
go back to reference Huan Y, Townsend R. The single pill triple combination of aliskeren, amlodipine and hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2012;13(16):2409–15.PubMedCrossRef Huan Y, Townsend R. The single pill triple combination of aliskeren, amlodipine and hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2012;13(16):2409–15.PubMedCrossRef
178.
go back to reference Rao NS, Oomman A, Bindumathi PL, et al. Efficacy and tolerability of fixed dose combination of metoprolol and amlodipine in Indian patients with essential hypertension. J Midlife Health. 2013;4(3):160–6.PubMedCentralPubMed Rao NS, Oomman A, Bindumathi PL, et al. Efficacy and tolerability of fixed dose combination of metoprolol and amlodipine in Indian patients with essential hypertension. J Midlife Health. 2013;4(3):160–6.PubMedCentralPubMed
179.
go back to reference Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO Trial. Adv Ther. 2014;31(3):333–44.PubMedCentralPubMedCrossRef Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO Trial. Adv Ther. 2014;31(3):333–44.PubMedCentralPubMedCrossRef
180.
go back to reference Ram CV. Fixed-dose triple combination treatments in the management of hypertension. Manag Care. 2013;22(12):45–55.PubMed Ram CV. Fixed-dose triple combination treatments in the management of hypertension. Manag Care. 2013;22(12):45–55.PubMed
181.
go back to reference Evans CD, Eurich DT, Lu X, et al. The association between market availability and adherence to antihypertensive medications: an observational study. Am J Hypertens. 2013;26(2):180–90.PubMedCrossRef Evans CD, Eurich DT, Lu X, et al. The association between market availability and adherence to antihypertensive medications: an observational study. Am J Hypertens. 2013;26(2):180–90.PubMedCrossRef
183.
go back to reference Houston MC. Nutrition and nutraceutical supplements for the treatment of hypertension: part 1. J Clin Hypertens (Greenwich). 2013;15:752–57. Houston MC. Nutrition and nutraceutical supplements for the treatment of hypertension: part 1. J Clin Hypertens (Greenwich). 2013;15:752–57.
184.
185.
go back to reference Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality. A detailed pooled analysis of the dose-response relationship. JAMA Intern Med. 2015;175(6):959–67.PubMedCrossRef Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality. A detailed pooled analysis of the dose-response relationship. JAMA Intern Med. 2015;175(6):959–67.PubMedCrossRef
186.
go back to reference Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease; a meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCentralPubMedCrossRef Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease; a meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCentralPubMedCrossRef
187.
go back to reference Turnbull F, Neal B, Ninomiya T, Blood Pressure Lowering Treatment Trialists’ Collaboration, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults; meta-analysis of randomized trials. BMJ. 2008;336(7653):1121–3.PubMedCrossRef Turnbull F, Neal B, Ninomiya T, Blood Pressure Lowering Treatment Trialists’ Collaboration, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults; meta-analysis of randomized trials. BMJ. 2008;336(7653):1121–3.PubMedCrossRef
188.
go back to reference Aronow WS. Multiple blood pressure medications and mortality among elderly individuals. JAMA. 2015;313:1362–3.PubMedCrossRef Aronow WS. Multiple blood pressure medications and mortality among elderly individuals. JAMA. 2015;313:1362–3.PubMedCrossRef
189.
190.
go back to reference Fick D, Semla T, Beizer J, et al. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc. 2012:1–16. Fick D, Semla T, Beizer J, et al. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc. 2012:1–16.
191.
go back to reference O’Mahony D, Gallager P, Ryan C, et al. STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med. 2010;1:45–51.CrossRef O’Mahony D, Gallager P, Ryan C, et al. STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med. 2010;1:45–51.CrossRef
192.
go back to reference Barochiner J, Alfie J, Aparicio L, et al. Orthostatic hypotension in treated hypertensive patients. Rom J Intern Med. 2012;50(3):203–9.PubMed Barochiner J, Alfie J, Aparicio L, et al. Orthostatic hypotension in treated hypertensive patients. Rom J Intern Med. 2012;50(3):203–9.PubMed
193.
go back to reference Reddy P, Dupree L. Approach to antihypertensive therapy. Am J Ther. 2015 (Epub ahead of print). Reddy P, Dupree L. Approach to antihypertensive therapy. Am J Ther. 2015 (Epub ahead of print).
194.
go back to reference Go AS, Bauman A, Coleman M, et al. An effective approach to high blood pressure control. A science advisory from the American Heart Association, the American College of Cardiology and the Centers for Disease Control and Prevention. J Am Coll Cardiol. 2014;63(12):1230–8. Go AS, Bauman A, Coleman M, et al. An effective approach to high blood pressure control. A science advisory from the American Heart Association, the American College of Cardiology and the Centers for Disease Control and Prevention. J Am Coll Cardiol. 2014;63(12):1230–8.
Metadata
Title
Tolerability of Antihypertensive Medications in Older Adults
Authors
Thiruvinvamalai S. Dharmarajan
Lekshmi Dharmarajan
Publication date
01-10-2015
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 10/2015
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0296-3

Other articles of this Issue 10/2015

Drugs & Aging 10/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.